Fate Therapeutics (FATE) Net Income towards Common Stockholders (2012 - 2026)
Fate Therapeutics (FATE) posted Net Income towards Common Stockholders of -$147.7 million for Q1 2026, down 354.5% on a QoQ basis from -$32.5 million in Q4 2025, and up 12.01% year-over-year from -$131.9 million in Q1 2025.
Fate Therapeutics (FATE) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends
Fate Therapeutics' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at -$147.7 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 12.01% year-over-year to -$147.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$300.5 million (up 69.45% YoY) and the FY2025 annual result came in at -$524.7 million, up 5.48% from the prior year.
- Net Income towards Common Stockholders was -$147.7 million for Q1 2026 at Fate Therapeutics, down from -$32.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$32.5 million in Q4 2025 and bottomed at -$420.0 million in Q4 2024.
- A 5-year average of -$179.6 million and a median of -$155.3 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 110.33% — and 2025, when it soared 92.26%.
- Fate Therapeutics' Net Income towards Common Stockholders stood at -$357.8 million in 2022, then dropped by 2.75% to -$367.6 million in 2023, then declined by 14.24% to -$420.0 million in 2024, then surged by 92.26% to -$32.5 million in 2025, then slumped by 354.5% to -$147.7 million in 2026.
- Business Quant data shows FATE's Net Income towards Common Stockholders at -$147.7 million in Q1 2026, -$32.5 million in Q4 2025, and -$75.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Fate Therapeutics | 288.82 Mn | 288.82 Mn | - | -147.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -147.72 Mn |
| Dec 31, 2025 | -32.50 Mn |
| Sep 30, 2025 | -75.29 Mn |
| Jun 30, 2025 | -44.97 Mn |
| Mar 31, 2025 | -167.88 Mn |
| Dec 31, 2024 | -419.96 Mn |
| Sep 30, 2024 | -199.90 Mn |
| Jun 30, 2024 | -195.91 Mn |
| Mar 31, 2024 | -104.14 Mn |
| Dec 31, 2023 | -367.62 Mn |
| Sep 30, 2023 | -213.12 Mn |
| Jun 30, 2023 | -122.00 Mn |
| Mar 31, 2023 | -90.96 Mn |
| Dec 31, 2022 | -357.79 Mn |
| Sep 30, 2022 | -155.28 Mn |
| Jun 30, 2022 | -267.67 Mn |
| Mar 31, 2022 | -90.06 Mn |
| Dec 31, 2021 | -295.89 Mn |
| Sep 30, 2021 | -241.90 Mn |
| Jun 30, 2021 | -127.26 Mn |